Video

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

Author(s):

Alice Mims, MD

In Partnership With:

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).

Related Videos
Ashkan Emadi, MD, PhD
Alexis LeVee, MD
Martin Dreyling, MD
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
John H. Strickler, MD
Junjie Li, MD
Peter Riedell, MD
Jorge Cortes, MD
Michael R. Bishop, MD
Lori A Leslie, MD
Related Content
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
January 6th 2025

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Margaret A. Shipp, MD, of Dana-Farber
December 31st 2024

Shipp’s Passion Leads to Transformative Research, Innovations in Lymphoma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Guillermo Garcia-Manero, MD
December 29th 2024

Paying It Forward: The Importance of Mentorship in a Medical Career

Joseph A. Sparano, MD, FACP
December 23rd 2024

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care